Cabotegravir | List of Frontiers open access articles

Perspective

Published on 14 Nov 2023

Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe

in HIV and STIs

Caroline Murombedzi
Libert Chirinda
Gift T. Chareka
Z. Mike Chirenje
Nyaradzo M. Mgodi

Frontiers in Reproductive Health

doi 10.3389/frph.2023.1279124

3,779 views
7 citations

Original Research

Published on 20 Sep 2023

Synthesis and biological evaluation of novel 1,2,3-triazole hybrids of cabotegravir: identification of potent antitumor activity against lung cancer

in Pharmacology of Anti-Cancer Drugs

Yajie Guo
Dan Sang
Bin Guo
Dan Wang
Xinyue Xu
Huili Wang
Cuilan Hou
Longfei Mao
Fang Li
Sanqiang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1265245

3,470 views
10 citations

Original Research

Published on 06 Oct 2023

Design and synthesis of cabotegravir derivatives bearing 1,2,3-triazole and evaluation of anti-liver cancer activity

in Pharmacology of Anti-Cancer Drugs

Huaxia Xie
Longfei Mao
Gaolu Fan
Ziyuan Wu
Yimian Wang
Xixi Hou
Jiangang Wang
Huili Wang
Ling Liu
Sanqiang Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1265289

3,731 views
15 citations

Mini Review

Published on 23 Oct 2024

Achieving HIV epidemic control through accelerating efforts to expand access to pre-exposure prophylaxis for people who inject drugs

in HIV and STIs

Lirica Nishimoto
Adaobi Lisa Olisa
Philip Imohi
Judy Chang
Chris Obermeyer
Dama Kabwali
Christopher Akolo

Frontiers in Reproductive Health

doi 10.3389/frph.2024.1438005

3,335 views

Original Research

Published on 15 Oct 2024

Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China

in Drugs Outcomes Research and Policies

Shiwen Chen
Yuhua Ruan
Lu Liu
Hengyan Pei
Yu Jiang
Tengda Huang
Yuxia Wei
Litai Qin
Xuebin Dai
Yu Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1367830

2,528 views
1 citation

Perspective

Published on 18 Apr 2024

The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development

in HIV and STIs

Katerina Chapman
Sergio Torres-Rueda
Mutsumi Metzler
Bethany Young Holt
Elijah Kahn-Woods
Douglas Thornton
Gabriela B. Gomez

Frontiers in Reproductive Health

doi 10.3389/frph.2024.1272950

2,473 views
1 citation

Original Research

Published on 30 May 2024

Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023)

in Infectious Diseases: Epidemiology and Prevention

Daniel Schmidt
Christian Kollan
Matthias Stoll

Frontiers in Public Health

doi 10.3389/fpubh.2024.1404255

3,052 views
2 citations

Original Research

Published on 09 Jan 2023

Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa

in Adolescent Reproductive Health and Well-being

Paballo Mataboge
Susan Nzenze
Nqaba Mthimkhulu
Mbali Mazibuko
Alison Kutywayo
Vusile Butler
Nicolette Naidoo
Saiqa Mullick

Frontiers in Reproductive Health

doi 10.3389/frph.2022.1081049

5,177 views
15 citations

Review

Published on 19 Nov 2024

Where do we go from here? Reconciling implementation failure of PrEP for Black women in the South. Leveraging critical realism to identify unaddressed barriers as we move forward

in HIV and STIs

Whitney C. Irie
Anais Mahone
Renee Heffron
Latesha Elopre

Frontiers in Reproductive Health

doi 10.3389/frph.2024.1449554

2,795 views
4 citations

Systematic Review

Published on 07 Jul 2021

Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials

in Drugs Outcomes Research and Policies

Gilbert Lazarus
Vincent Kharisma Wangsaputra
Christianto
Melva Louisa
Vivian Soetikno
Raph L. Hamers

Frontiers in Pharmacology

doi 10.3389/fphar.2021.664875

8,786 views
16 citations

Systematic Review

Published on 29 Sep 2023

Safety surveillance for PrEP in pregnant and breastfeeding women

in HIV and STIs

Lee Fairlie
Diane Lavies
Emma Kalk
Otty Mhlongo
Faeezah Patel
Karl-Günter Technau
Sana Mahtab
Dhayendre Moodley
Hasina Subedar
Saiqa Mullick

Frontiers in Reproductive Health

doi 10.3389/frph.2023.1221101

6,622 views
11 citations

Original Research

Published on 21 Feb 2023

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors

in In Vitro Toxicology

Emma G. Foster
Nicholas Y. Palermo
Yutong Liu
Benson Edagwa
Howard E. Gendelman
Aditya N. Bade

Frontiers in Toxicology

doi 10.3389/ftox.2023.1113032

3,695 views
6 citations

Brief Research Report

Published on 25 Apr 2022

Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro

in Infectious Diseases – Surveillance, Prevention and Treatment

Bethany S. Schneiderman
Michal S. Barski
Goedele N. Maertens

Frontiers in Medicine

doi 10.3389/fmed.2022.889621

5,941 views
12 citations

Original Research

Published on 07 Mar 2025

Perceived benefits and barriers to the use of long-acting injectable antiretroviral treatment among adolescents and young people living with HIV in Western Kenya: qualitative findings from the KuwaFree! LiveFree! Study

in Infectious Diseases: Pathogenesis and Therapy

Shukri A. Hassan
Dennis Munyoro
Mehar Maju
Whitney Biegon
Salim Bakari
Eunice Kaguiri
Anjellah Jumah
Mark Omollo
Valerie Obare
Caitlin Bernard

Frontiers in Medicine

doi 10.3389/fmed.2025.1518719

3,023 views

Original Research

Published on 24 Oct 2024

Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy

in Virology

Dorcas Maruapula
Doreen Ditshwanelo
Marea N. Pema
Ontlametse T. Bareng
Wonderful T. Choga
Natasha O. Moraka
Patrick T. Mokgethi
Kaelo K. Seatla
Catherine K. Koofhethile
Boitumelo J. Zuze

Frontiers in Microbiology

doi 10.3389/fmicb.2024.1482348

2,654 views
2 citations

Articles

Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe

Synthesis and biological evaluation of novel 1,2,3-triazole hybrids of cabotegravir: identification of potent antitumor activity against lung cancer

Design and synthesis of cabotegravir derivatives bearing 1,2,3-triazole and evaluation of anti-liver cancer activity

Achieving HIV epidemic control through accelerating efforts to expand access to pre-exposure prophylaxis for people who inject drugs

Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China

The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development

Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023)

Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa

Where do we go from here? Reconciling implementation failure of PrEP for Black women in the South. Leveraging critical realism to identify unaddressed barriers as we move forward

Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials

Safety surveillance for PrEP in pregnant and breastfeeding women

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors

Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro

Perceived benefits and barriers to the use of long-acting injectable antiretroviral treatment among adolescents and young people living with HIV in Western Kenya: qualitative findings from the KuwaFree! LiveFree! Study

Low prevalence of archived integrase strand transfer inhibitors resistance associated mutations in Botswana before the roll out of dolutegravir based first line antiretroviral therapy